HUP0202396A3 - Medicaments useful for treating fractures - Google Patents

Medicaments useful for treating fractures

Info

Publication number
HUP0202396A3
HUP0202396A3 HU0202396A HUP0202396A HUP0202396A3 HU P0202396 A3 HUP0202396 A3 HU P0202396A3 HU 0202396 A HU0202396 A HU 0202396A HU P0202396 A HUP0202396 A HU P0202396A HU P0202396 A3 HUP0202396 A3 HU P0202396A3
Authority
HU
Hungary
Prior art keywords
medicaments useful
treating fractures
fractures
treating
medicaments
Prior art date
Application number
HU0202396A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Royal Alexandra Hosp Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Alexandra Hosp Children filed Critical Royal Alexandra Hosp Children
Publication of HUP0202396A2 publication Critical patent/HUP0202396A2/hu
Publication of HUP0202396A3 publication Critical patent/HUP0202396A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU0202396A 1999-08-19 2000-08-17 Medicaments useful for treating fractures HUP0202396A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures

Publications (2)

Publication Number Publication Date
HUP0202396A2 HUP0202396A2 (hu) 2002-11-28
HUP0202396A3 true HUP0202396A3 (en) 2005-02-28

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202396A HUP0202396A3 (en) 1999-08-19 2000-08-17 Medicaments useful for treating fractures

Country Status (16)

Country Link
EP (1) EP1214079A4 (no)
JP (1) JP2003507426A (no)
KR (1) KR20020027562A (no)
CN (1) CN100345548C (no)
AU (1) AUPQ232599A0 (no)
BR (1) BR0013416A (no)
CA (1) CA2381302A1 (no)
HK (1) HK1048441B (no)
HU (1) HUP0202396A3 (no)
IL (1) IL148166A0 (no)
NO (1) NO20020784L (no)
NZ (1) NZ517538A (no)
PL (1) PL353485A1 (no)
SK (1) SK2382002A3 (no)
WO (1) WO2001013922A1 (no)
ZA (1) ZA200202160B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527351A (en) 2001-02-06 2005-01-28 Royal Alexandra Hosp Children Use of bisphosphonate for the treatment of osteonecrosis and for the management of patients at risk of developing ostenonecrosis
WO2002080933A1 (en) * 2001-04-03 2002-10-17 The Royal Alexandra Hospital For Children A drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
EP1508343B1 (en) * 2003-08-21 2015-11-04 AddBIO AB Bisphosponate coated implant device and method therefor
RU2326695C2 (ru) * 2003-09-19 2008-06-20 Пфайзер Продактс Инк. Фармацевтические композиции и способы, включающие комбинации 2-алкилиденовых производных 9-нор-витамина d и бисфосфоната
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
JP5426168B2 (ja) * 2005-10-27 2014-02-26 トーメン メディカル アーゲー 歯科インプラント及びその製造方法
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
RU2112515C1 (ru) * 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
AU703887B2 (en) * 1995-06-06 1999-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Also Published As

Publication number Publication date
ZA200202160B (en) 2003-08-27
PL353485A1 (en) 2003-11-17
WO2001013922A1 (en) 2001-03-01
HK1048441B (zh) 2008-02-22
CN100345548C (zh) 2007-10-31
EP1214079A1 (en) 2002-06-19
KR20020027562A (ko) 2002-04-13
CN1370071A (zh) 2002-09-18
SK2382002A3 (en) 2002-09-10
NZ517538A (en) 2003-07-25
CA2381302A1 (en) 2001-03-01
AUPQ232599A0 (en) 1999-09-09
NO20020784D0 (no) 2002-02-18
IL148166A0 (en) 2002-09-12
HK1048441A1 (en) 2003-04-04
BR0013416A (pt) 2002-04-30
JP2003507426A (ja) 2003-02-25
HUP0202396A2 (hu) 2002-11-28
NO20020784L (no) 2002-02-18
EP1214079A4 (en) 2004-03-24

Similar Documents

Publication Publication Date Title
HUP0200556A2 (en) Medicament for treating diabetes
EP1284728A4 (en) MEDICINES FOR TREATING ADDICTIC ADDICTION
PL350167A1 (en) Medicament for treating hypertension
GB9930570D0 (en) Therapy
GB9925136D0 (en) Novel treatment
GB9918760D0 (en) Topical treatment
GB9907243D0 (en) Therapy
PL349347A1 (en) Novel treatment
HUP0202396A3 (en) Medicaments useful for treating fractures
GB9900222D0 (en) Therapeutic compounds
ZA991786B (en) Therapeutic treatment for asthma.
HU9902296D0 (en) Pharmaceutical composition for treating caltification
GB0020261D0 (en) Therapeutic treatment
HUP0105469A3 (en) Therapeutic drugs comprising pyrroloazepines for treating intermittent claudication
HU9904711D0 (en) Set for fixation fractures
GB9924980D0 (en) Therapeutic treatment
GB9901505D0 (en) Therapeutic treatment
GB9908993D0 (en) Treatment
GB9909650D0 (en) Novel treatment
GB9916655D0 (en) Novel treatment
GB9920787D0 (en) Novel treatment
GB9920788D0 (en) Novel treatment
GB9912313D0 (en) Arthritis treatment
GB9923343D0 (en) Treatment system
GB9913509D0 (en) Heat treatment

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees